Global expansion Co-Diagnostics, Inc operates with international engagement including participation in Medical Korea 2026 and Global Health Exhibitions in Saudi Arabia, signaling readiness to partner with regional distributors, healthcare providers, and governments to deploy PCR technology in underserved markets.

Affordable PCR access The company emphasizes democratizing molecular diagnostics and launching an at home and point-of-care real-time PCR platform, which presents a compelling value proposition for payers, clinics, and retailers seeking cost-effective, scalable diagnostic solutions.

Strategic leadership Hiring a Chief Scientific Officer and actively expanding leadership suggests a focus on advancing the Co-Primers technology and accelerating development and commercialization of PCR Pro instruments, which can open collaboration for R&D partnerships and co-development deals.

Market-ready platform Patented Co-Primers technology combined with a dedicated instrument and tests positions Co-Dx to respond to global infectious disease testing needs, creating sales opportunities with hospitals, regional labs, and urgent-care networks seeking rapid, reliable PCR diagnostics.

Financial capacity With revenue in the tens of millions and recent funding activity including a $7M financing round, there is capital available to support channel development, regional deployments, and pilot programs with strategic distributors and healthcare providers.